Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Europe’s BAPS Swaminarayan Sanstha is supporting their community during the coronavirus pandemic by spreading awareness of the PRINCIPLE trial of Covid-19 treatments.

Exterior of the Hindu temple, BAPS Shri Swaminarayan Mandir, in Neasden, London © Shutterstock
The Neasden Temple, London

Led by Oxford University researchers, the PRINCIPLE trial is working across all UK communities to evaluate if treatment administered early in the course of the Covid-19 illness can help people aged over 50 recover quickly, without the need for hospital admission.

Sadhu Yogvivekdas, Head of the BAPS Shri Swaminarayan Sanstha, UK & Europe, explained details of the trial to its vast network of worshipers and followers as part of an online sermon, explaining that those with Covid-19 symptoms can join online from home or via GP practices across the country, without the need for face-to-face visits.

While developing grassroots partnerships has been a major focus of the trial’s recruitment strategy so far, recruiting people from Black, Asian and minority ethnic communities has been a particular challenge.

The full story is available on the Nuffield Department of Primary Care Health Sciences website

Find out more about the PRINCIPLE trial

 

Similar stories

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.